Abbott Laboratories

Current directors and officers who also hold a role at another S&P 500 company.

• Nancy McKinstryACN · DirectorMDLZ · Director
• Darren W. McDewGE · Director
• John G. StrattonGD · Director
• Kevin T. ConroyALGN · Director
• Michael O'GradyNTRS · CEO
• Michelle KumbierTDY · Director
• Robert J. AlpernABBV · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Apr 27, 2026

   On April 24, 2026, Kevin Conroy was named to the Abbott Laboratories’ (“Abbott”) Board of Directors. On April 24, 2026, Abbott shareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”) at the Annual Meeting of Shareholders. The 2026 Program was adopted by Abbott’s Board of Directors on February 20, 2026, subject to shareholder approval at the Annual Meeting. The 2026 Program replaces the Abbott Laboratories 2017 Incentive Stock Program, as amended and restated (the “2017 Program”), under which Abbott makes all of its equity-related incentive compensation awards.

   Read the 8-K filing
2. Dec 12, 2025

   On December 12, 2025, Nita Ahuja, M.D. was named to the Abbott Laboratories’ (“Abbott”) Board of Directors.

   Read the 8-K filing
3. May 1, 2025

   On April 25, 2025, Hubert L. Allen, Executive Vice President, General Counsel and Secretary, informed Abbott Laboratories that he plans to retire from the company after a period of transition.

   Read the 8-K filing
4. Nov 15, 2024

   As previously reported, Abbott has Agreements Regarding Change in Control (“Agreements”) with its named executive officers. The Agreements provide that if Abbott gives notification of extension before the Expiration Date (December 31, 2024), the Agreement’s term shall continue through the second anniversary of the Expiration Date. On November 12, 2024, Abbott notified the named executive officers that the term of the Agreements was extended through December 31, 2026.

   Read the 8-K filing
5. May 1, 2024

   On April 26, 2024, Robert E. Funck, Jr., Executive Vice President, Finance, informed Abbott Laboratories that he plans to retire from the company after 36 years of service, effective July 1, 2024.

   Read the 8-K filing
6. Jun 12, 2023

   Director or officer change (Item 5.02). Open the filing for details.

   Read the 8-K filing
7. Oct 21, 2022

   As previously reported, Abbott has Agreements Regarding Change in Control (“Agreements”) with its named executive officers. The Agreements provide that if Abbott gives notification of extension before the Expiration Date (December 31, 2022), the Agreement’s term shall continue through the second anniversary of the Expiration Date. On October 18, 2022, Abbott notified the named executive officers that the term of the Agreements was extended through December 31, 2024.

   Read the 8-K filing
8. Sep 15, 2022

   On September 15, 2022, Claire Babineaux-Fontenot was named to the Abbott Laboratories’ (“Abbott”) Board of Directors.

   Read the 8-K filing
9. Dec 13, 2021

   On December 9, 2021, Roxanne S. Austin informed the Abbott Laboratories Board of Directors of her decision not to stand for re-election at the end of her current term expiring at the 2022 annual shareholders meeting in April.

   Read the 8-K filing
10. Dec 10, 2021

    On December 9, 2021, Miles D. White informed the Abbott Laboratories (“Abbott”) Board of Directors that he will step down as Executive Chairman of the Board and as a director, effective December 10, 2021. On December 10, 2021, Abbott’s Board of Directors appointed Robert B. Ford, Abbott’s President and Chief Executive Officer and a director, to the additional position of Chairman of the Board, effective upon Mr. White’s resignation. A copy of Abbott’s press release announcing these changes is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

    Read the 8-K filing
11. Sep 1, 2021

    On August 30, 2021, Patricia P. Gonzalez was named to the Abbott Laboratories’ (“Abbott”) Board of Directors.

    Read the 8-K filing
12. Feb 19, 2021

    On February 18, 2021, Phebe N. Novakovic informed the Board of Directors of her decision not to stand for re-election at the end of her current term expiring at the 2021 annual shareholders meeting in April.

    Read the 8-K filing
13. Nov 20, 2020

    As previously reported, Abbott has Agreements Regarding Change in Control (“Agreements”) with its named executive officers, other than Miles D. White, Abbott’s Executive Chairman, who is not party to an Agreement. The Agreements provide that if Abbott gives notification of extension before the Expiration Date (December 31, 2020), the Agreement’s term shall continue through the second anniversary of the Expiration Date. On November 20, 2020, Abbott notified the named executive officers who are party to the Agreements that the term of the Agreements was extended through December 31, 2022.

    Read the 8-K filing
14. Feb 27, 2020

    Director or officer change (Item 5.02). Open the filing for details.

    Read the 8-K filing
15. Feb 11, 2020

    Director or officer change (Item 5.02). Open the filing for details.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.